You are here

  • Home
  • Archive
  • Volume 14, Issue 11
  • Longitudinal assessment of serum albumin levels with the risk of coronary artery calcification progression in an asymptomatic population of Korean adults: an observational cohort study

Article Text

Article menu
Cardiovascular medicine
Original research
Longitudinal assessment of serum albumin levels with the risk of coronary artery calcification progression in an asymptomatic population of Korean adults: an observational cohort study
  1. Ki-Bum Won1,
  2. Su-Yeon Choi2,
  3. Eun Ju Chun3,
  4. Sung Hak Park4,
  5. Jidong Sung5,
  6. Hae Ok Jung6,
  7. Hyuk Jae Chang7
  1. 1Cardiology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Republic of Korea
  2. 2Cardiology, Seoul National University Hospital, Seoul, Republic of Korea
  3. 3Radiology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  4. 4Radiology, Gangnam Heartscan Clinic, Seoul, Republic of Korea
  5. 5Cardiology, Samsung Medical Center, Seoul, Republic of Korea
  6. 6Cardiology, Seoul St. Mary's Hospital, Seoul, Republic of Korea
  7. 7Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
  1. Correspondence to Hyuk Jae Chang; hjchang{at}yuhs.ac

Abstract

Objectives This study evaluated the association between serum albumin levels and coronary artery calcification (CAC) progression in asymptomatic adults without hypoalbuminaemia at baseline.

Design Observational cohort study.

Setting Data from the Korea Initiatives on Coronary Artery Calcification (KOICA) which is a retrospective, single ethnicity, multicentre and observational registry were analysed.

Participants A total of 12 344 Korean adults with baseline albumin level of ≥3.5 g/dL (51.7±8.5 years; 84.3% male) were included. The median interscan period was 3.0 (2.0–4.8) years. All participants were stratified into three groups based on serum albumin tertile.

Primary and secondary outcome measures Association of serum albumin with the risk of CAC progression was analysed using multivariate logistic regression models with adjustment of interscan period. CAC progression was defined as a square root (√) transformed difference between the baseline and follow-up coronary artery calcium score (CACS) (Δ√transformed CACS) of ≥2.5. Annualised Δ√transformed CACS was defined as Δ√transformed CACS divided by interscan period.

Results With increasing serum albumin tertiles, the annualised Δ√transformed CACS (I (lowest): 0.16 (0–1.24) vs II: 0 (0–1.09) vs III (highest): 0 (0–1.01)) and the incidence of CAC progression (I: 36.6% vs II: 31.3% vs III: 25.0%) were decreased despite higher prevalence of hypertension, diabetes and hyperlipidaemia (all p<0.05). Serum albumin levels were inversely related to the annualised Δ√transformed CACS and the risk of CAC progression among overall participants. After adjusting for age, sex, hypertension, diabetes, hyperlipidaemia, obesity, current smoking, alcohol consumption, serum creatinine levels, baseline CACS and interscan period, this inverse association between serum albumin levels (per-1 g/dL increase) and the risk of CAC progression was consistently observed, especially in baseline CACS of 1–10 (OR: 0.392, 95% CI: 0.234 to 0.658) and 11–100 (OR: 0.580, 95% CI: 0.381 to 0.883) (all p<0.05).

Conclusions Serum albumin levels were inversely associated with the risk of CAC progression. This phenomenon was predominantly observed in CACS of 1–100 at baseline.

  • Cardiac Epidemiology
  • PUBLIC HEALTH
  • Cardiovascular imaging
  • PREVENTIVE MEDICINE

Data availability statement

Data are available upon reasonable request.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi-org.ezproxy.u-pec.fr/10.1136/bmjopen-2024-086075

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    STRENGTHS AND LIMITATIONS OF THIS STUDY

    • Longitudinal study with large sample size analysing the data of multicentre and observational cohort registry.

    • Assessment of the association of serum albumin levels with coronary artery calcification (CAC) progression focusing on the baseline coronary artery calcium score.

    • Adjustment of traditional risk factors to evaluate independent relationship between serum albumin levels and the risk of CAC progression.

    • Difficulty in generalising the results of current study because of the single-ethnicity participants.

    Introduction

    Atherosclerotic coronary heart disease (CHD) is a major cause of morbidity and mortality worldwide.1 In asymptomatic populations, the coronary artery calcium score (CACS) has been used to stratify cardiovascular (CV) risk based on the evidence that the CACS provides strong prognostic information across age, sex and ethnicity.2–4 Moreover, the progression of coronary artery calcification (CAC) has additive prognostic values beyond traditional risk factors, particularly in the absence of heavy baseline CAC.5 6 Thus, CACS determined using CT has a substantial role in assessing CV risk for primary prevention.7 8

    Albumin is a major protein accounting for more than half of the total serum composition. Previous studies have revealed that serum albumin has several physiological properties, including antioxidant, anti-inflammatory and antiplatelet aggregation activities.9–13 The normal range of serum albumin levels is defined to be within 3.5–5.5 g/dL in clinical practice. Recent evidence has suggested that low serum albumin levels are strongly associated with the increased risk of CHD and mortality beyond traditional risk factors.14–17 However, data regarding the association between serum albumin levels and coronary atherosclerotic changes in asymptomatic adults are lacking. In addition, although previous studies have revealed that (1) the absence of CAC confers a low CV event risk2 18 and (2) clinical risk factors are less predictive for the progression of coronary atherosclerosis compared with the baseline coronary plaque burden,19 little is known regarding the association of serum albumin levels with the risk of CAC progression according to baseline CAC status. Therefore, the present study aimed to evaluate the association between serum albumin levels and the risk of CAC progression in an asymptomatic population of Korean adults without hypoalbuminaemia at baseline.

    Methods

    Study population and design

    This study analysed the data of Korea Initiatives on Coronary Artery Calcification (KOICA) which is a retrospective, single-ethnicity, multicentre and observational registry with a self-referral setting for asymptomatic subjects who underwent general health checkups at six healthcare centres in South Korea (Severance Cardiovascular Hospital; Samsung Medical Centre; Seoul St. Mary’s Hospital; Seoul National University Hospital; Seoul National University Bundang Hospital; Gangnam Heartscan Clinic). A total of 93 914 patients were enrolled in the registry between 2003 and August 2017. Among these participants, 12 353 who underwent at least two CAC scans with available serum albumin level data were identified. After excluding nine patients with hypoalbuminaemia (serum albumin level<3.5 g/dL), 12 344 were included in the present study. All data were obtained during visits to each healthcare centre. Self-reported medical questionnaires were used to obtain information on medical histories. Information on the medical histories of hypertension, diabetes, hyperlipidaemia, current smoking and alcohol consumption status of each participant was systematically collected. Height, weight and blood pressure were measured during healthcare centre visits. Blood pressure was measured using an automatic manometer on the right arm after resting for at least 5 mins. Body mass index (BMI) was calculated as weight (kg)/height (m2). All blood samples, including those for total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), glucose, haemoglobin A1C (HbA1C), albumin and creatinine were obtained after at least 8 hours of fasting and analysed. Hypertension was defined as systolic blood pressure (SBP)≥140 mm Hg or diastolic blood pressure (DBP)≥90 mm Hg, previous diagnosis of hypertension or antihypertensive medication. Diabetes was defined as a fasting glucose level of ≥126 mg/dL, HbA1C level of ≥6.5%, a referral diagnosis of diabetes or receiving antidiabetic treatment. Hyperlipidaemia was defined as a total cholesterol level of ≥240 mg/dL, a referral diagnosis of hyperlipidaemia or receiving antihyperlipidemic treatment. Obesity was defined as a BMI of ≥25.0 kg/m2 following the Korean Society for the Study of Obesity Guidelines. Participants were categorised into three groups based on their serum albumin tertiles.

    In this study, CACS was measured based on the scoring system previously described by Agatston et al.20 The baseline CACS was divided into four groups: CACS of 0, 1–10, 11–100 and >100, respectively. The progression of CAC was defined as a difference of ≥2.5 between the square roots (√) of the baseline and follow-up CACS (Δ√transformed CACS),5 21 considering interscan variability and the proportion of baseline CACS of 0 (56.2%). Annualised Δ√transformed CAC was defined as Δ√transformed CAC divided by interscan period. All CT scans to assess CAC were obtained using >16-slice multidetector CT scanners (Siemens 16-slice Sensation (Siemens AG, Munich, Germany), Philips Brilliance 256 iCT (Philips Healthcare, Amsterdam, The Netherlands), Philips Brilliance 40 channel MDCT (Philips Healthcare) and GE 64-slice Lightspeed (GE Healthcare, Chicago, IL, USA)). The informed written consent for procedures was obtained from all participants at each of centres. All methods were performed following relevant guidelines and regulations. The appropriate institutional review board of Severance Cardiovascular Hospital approved the study protocol (IRB no: 4-2014-0309).

    Statistical analysis

    Continuous variables are expressed as the mean±SD or the median (IQR), and categorical variables are presented as absolute values and percentages. After checking the distribution status of independent variables, the one-way analysis of variance test or the Kruskal–Wallis test was used for continuous variables, and the χ2 test or Fisher’s exact test was used for categorical variables, as appropriate. Univariable regression analyses were performed to evaluate the relation of clinical variables with (1) annualised Δ√transformed CACS and (2) the risk of CAC progression. Subsequently, multiple logistic regression models were used to assess the association of serum albumin levels with the risk of CAC progression considering the baseline categorical CACS (model 1, adjusted for age, sex, hypertension, diabetes, hyperlipidaemia, obesity, current smoking, alcohol consumption and interscan period; model 2, model 1+serum creatinine levels and baseline CACS). The forced entry method was used to enter the independent variables into the multivariable regression analysis. All statistical analyses were performed using R (V.3.6.3; R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was set at p<0.05 in all analyses.

    Patient and public involvement

    Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

    Results

    Baseline characteristics

    Table 1 presents the baseline characteristics of the participants. The mean age of the participants was 51.7±8.5 years, and 10 400 (84.3%) were men. The mean age decreased with increasing serum albumin tertiles. In contrast, the mean SBP, DBP, total cholesterol, triglyceride, LDL-C, fasting glucose and HbA1C levels increased with increasing serum albumin levels. Similarly, the proportion of male sex and the prevalence of hypertension, diabetes, hyperlipidaemia and alcohol consumption increased with increasing serum albumin tertiles. Significant differences were not observed in the HDL-C and creatinine levels or in the prevalence of obesity and current smoking across the serum albumin tertiles.

    View this table:
    Table 1

    Baseline characteristics

    Baseline and changes of CAC according to the serum albumin tertiles

    The median interscan period was 3.0 (2.0–4.8) years. During follow-up, the mean changes of √transformed CACS and annualised √transformed CACS were decreased with increasing serum albumin tertiles. The incidence of the CAC progression in overall participants was 30.6%; it significantly decreased with increasing serum albumin tertiles. The incidence of CAC progression at baseline CACS of 0, 1–10, 11–100 and >100 was 13.0%, 57.6%, 50.4% and 52.6%, respectively; the progression of CAC was less observed with increasing serum albumin tertiles in all baseline CACS groups (table 2).

    View this table:
    Table 2

    Baseline and changes of CAC according to serum albumin tertiles

    Association between clinical variables and CAC changes

    Univariable linear regression analysis showed that age, male sex, hypertension, diabetes, hyperlipidaemia, obesity, current smoking, alcohol consumption, serum creatinine and baseline CACS were positively related to the annualised Δ √transformed CACS; in contrast, serum albumin levels were inversely related to the annualised Δ √transformed CACS. In univariable logistic regression analysis, age, male sex, hypertension, diabetes, hyperlipidaemia, obesity, alcohol consumption, serum creatinine level and baseline CACS were associated with an increased risk of progression of CAC. The results regarding the risk of CAC progression related to glucose, triglyceride, HDL-C and LDL-C are present in online supplemental table 1. Elevated serum albumin levels were associated with a decreased risk of progression of CAC (table 3). The results of the subgroup analysis of the estimated risk of serum albumin levels for CAC progression are presented in figure 1.

    Figure 1
    Figure 1

    Subgroup analysis for the association between serum albumin levels (per-1 g/dL increase) and the risk of CAC progression. CAC, coronary artery calcification.

    View this table:
    Table 3

    Association of individual clinical factor with CAC changes

    Serum albumin levels and CAC progression according to baseline CACS

    In multiple logistic regression models, serum albumin levels were significantly associated with the decreased risk of CAC progression in overall participants. Multiple linear regression models regarding the association between serum albumin levels and the annualised Δ √transformed CACS with consecutive adjustment of age, sex, SBP, fasting glucose, triglyceride, LDL-C, BMI, current smoking and alcohol consumption, serum creatinine levels and baseline CACS showed consistent results (online supplemental table 2). According to the categorical CACS at baseline, model 1 showed that serum albumin levels (per-1 g/dL increase) were consistently associated with the risk of CAC progression in participants with baseline CACS of 1–10 (OR: 0.396, 95% CI: 0.237 to 0.662; p<0.001) and 11–100 (OR: 0.603, 95% CI: 0.397 to 0.915; p=0.018). In model 2, this association was consistently observed in participants with baseline CACS of 1–10 (OR: 0.392, 95% CI: 0.234 to 0.658; p<0.001) and 11–100 (OR: 0.580, 95% CI: 0.381 to 0.883; p=0.011) (table 4).

    View this table:
    Table 4

    Serum albumin levels (per-1 g/dL increase) and the risk of CAC progression according to baseline CACS

    Discussion

    The present study observed that the incidence of CAC progression significantly decreased with increasing serum albumin levels despite a positive relationship between serum albumin levels and the prevalence of hypertension, diabetes and hyperlipidaemia in asymptomatic adults without hypoalbuminaemia at baseline. An inverse association between serum albumin levels and the risk of progression of CAC was consistently observed after adjusting for confounding factors. Notably, no significant association between serum albumin levels and the risk of progression of CAC was identified in participants with CACS of 0 as well as in those with CACS of >100 at baseline. These results suggest that high serum albumin levels have a protective effect for the progression of CAC in asymptomatic adults, particularly in those with CACS of 1–100 at baseline.

    Several studies have reported a positive association between serum albumin levels and metabolic risk factors, such as blood pressure, insulin resistance and lipid profile.22–26 A recent cohort study from the Kuopio Ischaemic Heart Disease population found a linear and positive association between serum albumin levels and type 2 diabetes but not improving diabetes risk prediction during a mean follow-up of 20.4 years.27 Similar to the previous data reported by Danesh et al in their cross-sectional investigation of individuals with no history of CHD,25 we observed that serum albumin levels were positively associated with SBP, DBP and triglyceride and LDL-C levels among our participants without hypoalbuminaemia at baseline (online supplemental table 3). Although the mechanistic pathways for this association between serum albumin and metabolic disorders are unclear, a higher intake of dietary protein reportedly contributes to the positive association between serum albumin levels and metabolic syndrome.28 Interestingly, despite a positive relation of serum albumin levels with metabolic abnormalities, numerous studies have shown that serum albumin levels are inversely related to the prognosis with a cardioprotective effect.14–17

    It is well known that serum albumin has an essential blood antioxidant property as well as physiological activities including anti-inflammation and antiplatelet aggregation.9–13 29 Based on these findings, several studies have evaluated the relation between serum albumin levels and subclinical atherosclerosis. The NHLBI (National Heart, Lung and Blood Institute) Family Heart Study reported that lower serum albumin levels were not associated with an increased risk of prevalent carotid atherosclerosis in men or women among 2072 participants.30 However, Ishizaka et al demonstrated somewhat different results that higher serum albumin levels were inversely associated with the prevalence of early carotid atherosclerosis, although they were positively associated with the prevalence of metabolic syndrome in 8142 Japanese individuals.26 To the best of our knowledge, there are no studies with a large sample size on the effect of serum albumin levels on coronary atherosclerotic changes, particularly in conditions without hypoalbuminaemia. In this study, we observed an independent and inverse association between serum albumin levels and the progression of CAC in 12 344 asymptomatic participants with normal range of serum albumin levels beyond traditional risk factors, particularly in those with baseline CACS of 1–100. This finding suggests that serum albumin has antiatherogenic effects, irrespective of its positive association with metabolic abnormalities. However, the superior utility of high serum albumin levels for improving CV risk prediction over and above traditional risk factors is questionable. Also, the present study could not evaluate the association of serum albumin levels with non-calcified plaques or vulnerable plaques in coronary arteries because these data are based on the evaluation of CACS performed in asymptomatic adult population. Further large-scale prospective investigations are required to confirm these issues.

    The CONFRIM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicentre) substudy with a mean follow-up of 5.9±1.2 years recently identified that further prognostic benefit was not offered by coronary CT angiography findings over CACS and traditional risk factors in 1226 asymptomatic adults.31 Blaha et al18 reported that the absence of CAC predicted survival, with 10 year event rates of approximately 1% in 44 052 consecutive asymptomatic patients referred for CAC testing during a mean follow-up of 5.6±2.6 years. Similarly, the MESA (Multi-Ethnic Study of Atherosclerosis) study found consistent results among 6722 participants during a median follow-up of 3.8 years, irrespective of racial and ethnic differences.2 In this study, despite the independent and inverse association between serum albumin levels and the progression of CAC in overall participants, this phenomenon was not observed in participants without CAC or those with CACS>100 at baseline. These results indicate that (1) the absence of CAC reflects a low CV risk status, which is less affected by serum albumin levels in asymptomatic populations and (2) it is hard to predict the progression of CAC using specific biomarkers in condition with CACS of >100 at baseline alike previous KOICA studies have suggested.32 33

    The strength of this study is that the risk of CAC progression is assessed in asymptomatic adult population without heavy CAC at baseline. The proportion of CACS>400 was only 2.6% in the present study. According to the HNR (Heinz Nixdorf Recall) study,6 repeat CT scans after 5 years provided the readjustment of risk attributable to the increased risk in baseline CACS<400. However, although a high CV risk was present in baseline CACS more than 400, additional evaluation of CACS could not add the prognostic value in this condition. Additionally, the PARADIGM (Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging) registry, baseline coronary plaque burden was the most important factor, when compared with clinical and laboratory factors, in identifying patients at the risk of rapid plaque progression.19 These findings emphasise the significance of early detecting both the presence of subclinical coronary atherosclerosis and its progression.

    This study had some limitations. First, this study was performed in asymptomatic adult population who voluntarily participated in the health check-ups, which may have resulted in a selection bias. Second, this was a retrospective study, which may have been influenced by unidentified confounders. Third, data on the participants’ physical activity were unavailable. Fourth, we could not control the effects of medications for hypertension, diabetes and hyperlipidaemia on the progression of CAC because of the observational design. Fifth, the sample size of baseline CACS>100 was relatively small compared with that of other baseline categorical CACS. Sixth, different CT scanners were used among the participating centres; however, all participants were examined using the same CT scanner with identical ECG-triggering method during the initial and follow-up image acquisitions. Also, CAC progression was defined with the SQRT method, considering interscan variability in the present study.5 21 Seventh, the present study did not perform the variability analysis based on the strong evidence regarding variability and reproducibility of CACS measurement.21 34 35 Eighth, we only evaluated the association of the baseline serum albumin levels with CAC progression; any consecutive serum albumin changes during follow-up were not confirmed. Finally, this study included only a Korean population, which may limit generalisation. Nevertheless, this study is unique in that we evaluated the association between serum albumin levels and the risk of CAC progression after considering baseline CAC status in an asymptomatic Asian population with normal serum albumin levels.

    Conclusions

    The current study observes that serum albumin levels have an independent and inverse association with the progression of CAC despite their positive relation with metabolic abnormalities in asymptomatic adults without hypoalbuminaemia, particularly in those with CACS of 1–100 at baseline. Considering the interaction between clinical variables and serum albumin levels regarding the risk of CAC progression in subgroup analysis, further prospective investigations to evaluate the significance of serum albumin levels for subclinical coronary atherosclerosis focusing on diabetes and hyperlipidaemia should be necessary.

    Data availability statement

    Data are available upon reasonable request.

    Ethics statements

    Patient consent for publication

    Ethics approval

    This study involves human participants and was approved by the appropriate institutional review board of Severance Cardiovascular Hospital (IRB no: 4-2014-0309). Participants gave informed consent to participate in the study before taking part.

    References

    1. ↵
      1. Smith SC,
      2. Jackson R,
      3. Pearson TA, et al
      . Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation 2004;109:3112–21. doi:10.1161/01.CIR.0000133427.35111.67
      OpenUrlFREE Full Text
    2. ↵
      1. Detrano R,
      2. Guerci AD,
      3. Carr JJ, et al
      . Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336–45. doi:10.1056/NEJMoa072100
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      1. Erbel R,
      2. Möhlenkamp S,
      3. Moebus S, et al
      . Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010;56:1397–406. doi:10.1016/j.jacc.2010.06.030
      OpenUrlFREE Full Text
    4. ↵
      1. Budoff MJ,
      2. Shaw LJ,
      3. Liu ST, et al
      . Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 2007;49:1860–70. doi:10.1016/j.jacc.2006.10.079
      OpenUrlFREE Full Text
    5. ↵
      1. Budoff MJ,
      2. Hokanson JE,
      3. Nasir K, et al
      . Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Imaging 2010;3:1229–36. doi:10.1016/j.jcmg.2010.08.018
      OpenUrlAbstract/FREE Full Text
    6. ↵
      1. Lehmann N,
      2. Erbel R,
      3. Mahabadi AA, et al
      . Value of Progression of Coronary Artery Calcification for Risk Prediction of Coronary and Cardiovascular Events: Result of the HNR Study (Heinz Nixdorf Recall). Circulation 2018;137:665–79. doi:10.1161/CIRCULATIONAHA.116.027034
      OpenUrlAbstract/FREE Full Text
    7. ↵
      1. Greenland P,
      2. LaBree L,
      3. Azen SP, et al
      . Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004;291:210–5. doi:10.1001/jama.291.2.210
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      1. Agarwal S,
      2. Cox AJ,
      3. Herrington DM, et al
      . Coronary calcium score predicts cardiovascular mortality in diabetes: diabetes heart study. Diabetes Care 2013;36:972–7. doi:10.2337/dc12-1548
      OpenUrlAbstract/FREE Full Text
    9. ↵
      1. Arques S,
      2. Ambrosi P
      . Human serum albumin in the clinical syndrome of heart failure. J Card Fail 2011;17:451–8. doi:10.1016/j.cardfail.2011.02.010
      OpenUrlCrossRefPubMed
    10. ↵
      1. Zhang WJ,
      2. Frei B
      . Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res 2002;55:820–9. doi:10.1016/s0008-6363(02)00492-3
      OpenUrlCrossRefPubMed
    11. ↵
      1. Wiedermann CJ
      . Anti-inflammatory activity of albumin. Crit Care Med 2007;35:981–2. doi:10.1097/01.ccm.0000257234.87784.91
      OpenUrlPubMed
    12. ↵
      1. Anraku M,
      2. Chuang VTG,
      3. Maruyama T, et al
      . Redox properties of serum albumin. Biochim Biophys Acta 2013;1830:5465–72. doi:10.1016/j.bbagen.2013.04.036
      OpenUrlCrossRefPubMed
    13. ↵
      1. Paar M,
      2. Rossmann C,
      3. Nusshold C, et al
      . Anticoagulant action of low, physiologic, and high albumin levels in whole blood. PLoS One 2017;12:e0182997. doi:10.1371/journal.pone.0182997
    14. ↵
      1. Nelson JJ,
      2. Liao D,
      3. Sharrett AR, et al
      . Serum albumin level as a predictor of incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000;151:468–77. doi:10.1093/oxfordjournals.aje.a010232
      OpenUrlPubMedWeb of Science
    15. ↵
      1. Shaper AG,
      2. Wannamethee SG,
      3. Whincup PH
      . Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J Clin Epidemiol 2004;57:195–202. doi:10.1016/j.jclinepi.2003.07.001
      OpenUrlCrossRefPubMed
    16. ↵
      1. Djoussé L,
      2. Rothman KJ,
      3. Cupples LA, et al
      . Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation 2002;106:2919–24. doi:10.1161/01.cir.0000042673.07632.76
      OpenUrlAbstract/FREE Full Text
    17. ↵
      1. Yang Q,
      2. He Y-M,
      3. Cai D-P, et al
      . Risk burdens of modifiable risk factors incorporating lipoprotein (a) and low serum albumin concentrations for first incident acute myocardial infarction. Sci Rep 2016;6:35463. doi:10.1038/srep35463
      OpenUrlPubMed
    18. ↵
      1. Blaha M,
      2. Budoff MJ,
      3. Shaw LJ, et al
      . Absence of coronary artery calcification and all-cause mortality. JACC Cardiovasc Imaging 2009;2:692–700. doi:10.1016/j.jcmg.2009.03.009
      OpenUrlAbstract/FREE Full Text
    19. ↵
      1. Han D,
      2. Kolli KK,
      3. Al’Aref SJ, et al
      . Machine Learning Framework to Identify Individuals at Risk of Rapid Progression of Coronary Atherosclerosis: From the PARADIGM Registry. J Am Heart Assoc 2020;9:e013958. doi:10.1161/JAHA.119.013958
    20. ↵
      1. Agatston AS,
      2. Janowitz WR,
      3. Hildner FJ, et al
      . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32. doi:10.1016/0735-1097(90)90282-t
      OpenUrlFREE Full Text
    21. ↵
      1. Hokanson JE,
      2. MacKenzie T,
      3. Kinney G, et al
      . Evaluating changes in coronary artery calcium: an analytic method that accounts for interscan variability. AJR Am J Roentgenol 2004;182:1327–32. doi:10.2214/ajr.182.5.1821327
      OpenUrlCrossRefPubMedWeb of Science
    22. ↵
      1. Hu H,
      2. Sparrow D,
      3. Weiss S
      . Association of serum albumin with blood pressure in the normative aging study. Am J Epidemiol 1992;136:1465–73. doi:10.1093/oxfordjournals.aje.a116467
      OpenUrlPubMed
    23. ↵
      1. Tell GS,
      2. Rutan GH,
      3. Kronmal RA, et al
      . Correlates of blood pressure in community-dwelling older adults. The Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. Hypertension 1994;23:59–67. doi:10.1161/01.hyp.23.1.59
      OpenUrl
    24. ↵
      1. Høstmark AT,
      2. Tomten SE,
      3. Berg JE
      . Serum albumin and blood pressure: a population-based, cross-sectional study. J Hypertens 2005;23:725–30. doi:10.1097/01.hjh.0000163139.44094.1d
      OpenUrlCrossRefPubMedWeb of Science
    25. ↵
      1. Danesh J,
      2. Muir J,
      3. Wong YK, et al
      . Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 1999;20:954–9. doi:10.1053/euhj.1998.1309
      OpenUrlCrossRefPubMedWeb of Science
    26. ↵
      1. Ishizaka N,
      2. Ishizaka Y,
      3. Nagai R, et al
      . Association between serum albumin, carotid atherosclerosis, and metabolic syndrome in Japanese individuals. Atherosclerosis 2007;193:373–9. doi:10.1016/j.atherosclerosis.2006.06.031
      OpenUrlCrossRefPubMed
    27. ↵
      1. Kunutsor SK,
      2. Khan H,
      3. Laukkanen JA
      . Serum albumin concentration and incident type 2 diabetes risk: new findings from a population-based cohort study. Diabetologia 2015;58:961–7. doi:10.1007/s00125-015-3520-0
      OpenUrlCrossRefPubMed
    28. ↵
      1. Cho HM,
      2. Kim HC,
      3. Lee J-M, et al
      . The association between serum albumin levels and metabolic syndrome in a rural population of Korea. J Prev Med Public Health 2012;45:98–104. doi:10.3961/jpmph.2012.45.2.98
      OpenUrlPubMed
    29. ↵
      1. Roche M,
      2. Rondeau P,
      3. Singh NR, et al
      . The antioxidant properties of serum albumin. FEBS Lett 2008;582:1783–7. doi:10.1016/j.febslet.2008.04.057
      OpenUrlCrossRefPubMedWeb of Science
    30. ↵
      1. Djoussé L,
      2. Rothman KJ,
      3. Cupples LA, et al
      . Relation between serum albumin and carotid atherosclerosis: the NHLBI Family Heart Study. Stroke 2003;34:53–7. doi:10.1161/01.str.0000048675.97975.84
      OpenUrlAbstract/FREE Full Text
    31. ↵
      1. Cho I,
      2. Al’Aref SJ,
      3. Berger A, et al
      . Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study. Eur Heart J 2018;39:934–41. doi:10.1093/eurheartj/ehx774
      OpenUrlPubMed
    32. ↵
      1. Won K-B,
      2. Park EJ,
      3. Han D, et al
      . Triglyceride glucose index is an independent predictor for the progression of coronary artery calcification in the absence of heavy coronary artery calcification at baseline. Cardiovasc Diabetol 2020;19:34. doi:10.1186/s12933-020-01008-5
    33. ↵
      1. Won K-B,
      2. Han D,
      3. Lee JH, et al
      . Atherogenic index of plasma and coronary artery calcification progression beyond traditional risk factors according to baseline coronary artery calcium score. Sci Rep 2020;10:21324. doi:10.1038/s41598-020-78350-x
    34. ↵
      1. Halliburton SS,
      2. Stillman AE,
      3. Lieber M, et al
      . Potential clinical impact of variability in the measurement of coronary artery calcification with sequential MDCT. AJR Am J Roentgenol 2005;184:643–8. doi:10.2214/ajr.184.2.01840643
      OpenUrlPubMed
    35. ↵
      1. Oudkerk M,
      2. Stillman AE,
      3. Halliburton SS, et al
      . Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. Eur Radiol 2008;18:2785–807. doi:10.1007/s00330-008-1095-6
      OpenUrlCrossRefPubMedWeb of Science

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Footnotes

    • Contributors Study hypothesis and design: K-BW and HJC. Data acquisitions: K-BW, S-YC, EJC, SHP, JS, HOJ and HJC. Statistical analyses: K-BW and HJC. Writing of the initial versions of the manuscript: K-BW. Responsible for the overall content as the guarantor: HJC. All authors read, reviewed and provided feedback for the final manuscript.

    • Funding This research was supported by the Korean Medical Device Development Fund grant funded by the Korean government (Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, the Ministry of Food and Drug Safety) (project number: 1711139017).

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.